Results of cost-effectiveness study presented at EULAR 2019 congress

Celine van de Laar, researcher at TiH, today presented the results from a Monte Carlo simulation study at the Annual European Congress of Rheumatology. The study examined the cost-effectiveness of a JAK1/JAK2-inhibitor (baricitinib) instead of a biological DMARD (adalimumab) as second-line treatment in rheumatoid arthritis being treated in a treat-to-target strategy. The study indicated that the use of a JAK1/JAK2-inhibitor is cost-effective over 5 years.

The study was sponsored by Eli Lilly and Company. The published abstract of the presentation can be found here.